Switching From Semaglutide to Tirzepatide: Washout, Dose & What to Expect (2026)

The short version: you finish your last week of semaglutide, then start tirzepatide on your next scheduled weekly dose — roughly 3 to 7 days later — and you start at the lowest tirzepatide dose, 2.5 mg once weekly, regardless of how high your semaglutide dose was. No long washout is needed because semaglutide clears over about a week and because you begin tirzepatide low and titrate up. People switch for three honest reasons: hitting a weight-loss plateau and wanting the greater average loss the dual GIP/GLP-1 tirzepatide produced versus semaglutide head-to-head;^[1] tolerability (some people handle tirzepatide's gastrointestinal side effects better); or cost and access. But switching is not automatically better for everyone — you re-experience early-titration nausea, appetite and food noise return during the gap and at the low starting dose, and it takes several weeks to re-titrate to an effective dose. There is no validated semaglutide-to-tirzepatide conversion chart, and anyone selling one is guessing. This is general information, not medical advice — switch only under your prescriber's direction. See tirzepatide vs semaglutide and the Mounjaro drug page for the full picture.

Why people switch from semaglutide to tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide acts on the GLP-1 receptor alone. In the SURPASS-2 head-to-head trial in adults with type 2 diabetes, tirzepatide produced greater average weight reduction than semaglutide 1 mg across its dose tiers.^[1] In the obesity programs, tirzepatide at its top dose in SURMOUNT-1 produced about a fifth of body weight lost,^[2] versus roughly 15% for semaglutide 2.4 mg in STEP-1^[3] — the trials were not a direct head-to-head in obesity, but the magnitude difference is the reason most people consider the switch.

In practice the three reasons people switch are:

• Hitting a plateau or wanting more weight loss. If you have genuinely stalled on a well-titrated semaglutide dose, the larger average loss tirzepatide produced head-to-head is the main draw.^[1] But a true plateau has to be distinguished from not-yet-fully-titrated dosing or lifestyle drift — see the plateau section below.
• Tolerability. The side-effect classes overlap (both are GLP-1-class drugs with the same gastrointestinal profile), but some people simply tolerate one molecule better than the other. Switching for tolerability is reasonable, with the caveat that the new drug resets you to early-titration side effects.
• Cost and access. Pricing, insurance coverage, manufacturer cash-pay channels, and supply can all push a switch in either direction. This is a practical reason, not a clinical one.

The honest framing: tirzepatide is not automatically better for everyone. It produces greater average loss in trials, but averages hide individual variation — some people do very well on semaglutide and gain nothing by switching, and everyone pays the re-titration tax of returning side effects and weeks of lower dosing. The decision belongs with your prescriber, weighed against your own response, tolerability, and access.

The washout and timing — about a 3-7 day gap

Semaglutide has a long elimination half-life of roughly one week, which is why it is dosed once weekly. Because of that, the standard approach to switching is simple: finish your semaglutide week, then start tirzepatide on your next scheduled weekly dose — about 7 days after your last semaglutide injection, which in practice means roughly a 3 to 7 day gap depending on your schedule.

You do not need a long drug-free washout. The reason is twofold: semaglutide is already clearing over that week, and you are starting tirzepatide at the lowest dose, so the small amount of overlapping residual semaglutide is not a dose-stacking concern in the way starting a high tirzepatide dose would be. The practical detail people miss is that as semaglutide fades during the gap and the new low tirzepatide dose has not yet built up, appetite and "food noise" can briefly return — that is expected, not a sign the switch failed. For the full clearance timeline, see how long semaglutide stays in your system.

The dose — you do not dose-match

This is the single most important point on the page: you do not match your semaglutide dose. Regardless of whether you were on 1 mg, 2 mg, or the full 2.4 mg of semaglutide, you restart titration at the lowest tirzepatide dose — 2.5 mg once weekly — and titrate up in steps of at least 4 weeks, exactly as the Mounjaro and Zepbound labels direct for any new start.^[4][5] Tirzepatide and semaglutide are different molecules acting on different receptor targets, and there is no exact dose equivalence between them.

Because there is no equivalence, there is no validated conversion chart. Any chart claiming "2.4 mg semaglutide equals X mg tirzepatide" is guessing — it has no trial or FDA basis, and following it risks starting too high and triggering severe gastrointestinal side effects. The label-directed, restart-low method is the standard for weight management. It is worth noting that a small 2025 report (Kurinami and colleagues) described earlier dose escalation of tirzepatide in some patients switching from semaglutide for type 2 diabetes,^[6] but that is a specific clinical context decided by a prescriber, not a general license to skip the 2.5 mg start or to dose-match.

What to expect during the switch

Set expectations honestly before you switch, because the first weeks usually feel like a step backward before they feel like a step forward:

• Appetite and food noise return — temporarily. During the 3 to 7 day gap and at the low 2.5 mg starting dose, the strong appetite suppression you had on a fully-titrated semaglutide dose fades, and cravings and "food noise" can come back for a few weeks. This is the most common surprise and it is expected.
• Gastrointestinal side effects reset. Starting tirzepatide at 2.5 mg means you re-experience the early-titration nausea, and possibly diarrhea, constipation, or reflux, that you had already moved past on semaglutide. The GI clock effectively restarts at zero.^[4]
• Re-titration takes weeks. Because you climb from 2.5 mg in 4-week steps, it takes several weeks to months to reach an effective tirzepatide dose. Do not expect instant, bigger results in week one — the greater weight loss tirzepatide can produce shows up only once you are titrated to an effective dose.^[4][5]
• A possible brief weight stall or small regain. With appetite returning and the new dose still low, some people see the scale flatten or tick up briefly during the transition. It typically resolves as titration proceeds.

Should you switch for a plateau?

A plateau is one of the best reasons to switch — but only a true plateau. Before switching, it is worth confirming that you are actually stalled on an optimized semaglutide dose, rather than simply not yet fully titrated, or experiencing the normal lifestyle drift (calories creeping up, activity down, sleep and stress off) that can mimic a plateau. Switching molecules will not fix a problem that a dose increase or a lifestyle reset would solve, and it costs you weeks of re-titration.

Our GLP-1 plateau decision guide walks through how to tell a genuine plateau from the alternatives step by step. If, after that, you and your prescriber conclude you have plateaued on an effective semaglutide dose, switching to tirzepatide for its greater average effect is a sound, evidence-aligned move^[1] — made together, not unilaterally.

Muscle, lean mass, and safety

Tirzepatide carries the same class warnings and precautions as semaglutide — gastrointestinal effects, the risk of dehydration and acute kidney injury from severe GI symptoms, gallbladder events, pancreatitis, and the labeled thyroid C-cell tumor boxed warning seen with the GLP-1 class — so switching does not let you set safety aside.^[4][5] As with any rapid weight loss, a meaningful share of the weight lost can be lean mass, so protecting muscle with adequate protein and resistance training matters as much on tirzepatide as it did on semaglutide; see protecting muscle on tirzepatide.

Above all, this must be a prescriber-led switch. The timing, the 2.5 mg restart, the titration pace, any adjustment to other glucose-lowering medications, and the monitoring all belong to your clinician — not to a conversion chart or a forum post. If you are choosing where to be managed, compare the best tirzepatide providers.

Step-by-step: how the switch works

If you have decided, with your prescriber, that you are switching to tirzepatide, the vetted providers below can manage the start and titration. We list them for convenience — the clinical decision and the supervision are what matter most.